FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206296392> ?p ?o ?g. }

• W4206296392 endingPage "584" @default.
• W4206296392 startingPage "577" @default.
• W4206296392 abstract "Vorolanib (CM082) is a multi-targeted tyrosine kinase receptor inhibitor with a short half-life and limited tissue accumulation that has been shown to reduce choroidal neovascularization in rats. In this preclinical study, vorolanib demonstrated competitive binding and inhibitory activities with KDR, PDGFRβ, FLT3, and C-Kit, and inhibited RET and AMPKα1 more weakly than sunitinib, indicating more stringent kinase selectivity. Vorolanib inhibited vascular endothelial growth factor (VEGF)-induced proliferation of human umbilical vein endothelial cells (HUVECs) and HUVEC tube formation in vitro. In mouse xenograft models, vorolanib inhibited tumor growth of MV-4-11, A549, 786-O, HT-29, BxPC-3, and A375 cells in a dose-dependent fashion. Complete tumor regression was achieved in the MV-4-11 xenograft model. No significant toxicities were observed in vorolanib groups, whereas a significant negative impact on body weights was observed in the sunitinib group at a dose of 40 mg/kg qd. Overall, vorolanib is a novel multi-kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity that is potentially less toxic than other similar kinase inhibitors. Vorolanib (CM082) is a multi-targeted tyrosine kinase receptor inhibitor with a short half-life and limited tissue accumulation that has been shown to reduce choroidal neovascularization in rats. In this preclinical study, vorolanib demonstrated competitive binding and inhibitory activities with KDR, PDGFRβ, FLT3, and C-Kit, and inhibited RET and AMPKα1 more weakly than sunitinib, indicating more stringent kinase selectivity. Vorolanib inhibited vascular endothelial growth factor (VEGF)-induced proliferation of human umbilical vein endothelial cells (HUVECs) and HUVEC tube formation in vitro. In mouse xenograft models, vorolanib inhibited tumor growth of MV-4-11, A549, 786-O, HT-29, BxPC-3, and A375 cells in a dose-dependent fashion. Complete tumor regression was achieved in the MV-4-11 xenograft model. No significant toxicities were observed in vorolanib groups, whereas a significant negative impact on body weights was observed in the sunitinib group at a dose of 40 mg/kg qd. Overall, vorolanib is a novel multi-kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity that is potentially less toxic than other similar kinase inhibitors." @default.
• W4206296392 created "2022-01-25" @default.
• W4206296392 creator A5003642180 @default.
• W4206296392 creator A5044319437 @default.
• W4206296392 creator A5058684604 @default.
• W4206296392 creator A5062737955 @default.
• W4206296392 creator A5068205782 @default.
• W4206296392 date "2022-03-01" @default.
• W4206296392 modified "2023-10-17" @default.
• W4206296392 title "Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity" @default.
• W4206296392 cites W1643211657 @default.
• W4206296392 cites W1918989451 @default.
• W4206296392 cites W1978139448 @default.
• W4206296392 cites W1980174503 @default.
• W4206296392 cites W1985359220 @default.
• W4206296392 cites W2007553857 @default.
• W4206296392 cites W2032696713 @default.
• W4206296392 cites W2039155298 @default.
• W4206296392 cites W2074256954 @default.
• W4206296392 cites W2096523159 @default.
• W4206296392 cites W2103430398 @default.
• W4206296392 cites W2110697333 @default.
• W4206296392 cites W2113788015 @default.
• W4206296392 cites W2121311115 @default.
• W4206296392 cites W2123334268 @default.
• W4206296392 cites W2134131507 @default.
• W4206296392 cites W2134744700 @default.
• W4206296392 cites W2139511378 @default.
• W4206296392 cites W2140626630 @default.
• W4206296392 cites W2142859819 @default.
• W4206296392 cites W2149032069 @default.
• W4206296392 cites W2149158668 @default.
• W4206296392 cites W2155704762 @default.
• W4206296392 cites W2164765170 @default.
• W4206296392 cites W2172261154 @default.
• W4206296392 cites W2398355991 @default.
• W4206296392 cites W2414493062 @default.
• W4206296392 cites W2563522215 @default.
• W4206296392 cites W2580449060 @default.
• W4206296392 cites W2758950172 @default.
• W4206296392 cites W2759314369 @default.
• W4206296392 cites W2766794307 @default.
• W4206296392 cites W2767336741 @default.
• W4206296392 cites W2803804327 @default.
• W4206296392 cites W2890131261 @default.
• W4206296392 cites W2890714997 @default.
• W4206296392 cites W2903138249 @default.
• W4206296392 cites W2981342572 @default.
• W4206296392 cites W2997946428 @default.
• W4206296392 cites W2998819969 @default.
• W4206296392 cites W3001475835 @default.
• W4206296392 cites W3129961448 @default.
• W4206296392 cites W4244491773 @default.
• W4206296392 cites W748554551 @default.
• W4206296392 doi "https://doi.org/10.1016/j.omto.2022.01.001" @default.
• W4206296392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35252556" @default.
• W4206296392 hasPublicationYear "2022" @default.
• W4206296392 type Work @default.
• W4206296392 citedByCount "5" @default.
• W4206296392 countsByYear W42062963922023 @default.
• W4206296392 crossrefType "journal-article" @default.
• W4206296392 hasAuthorship W4206296392A5003642180 @default.
• W4206296392 hasAuthorship W4206296392A5044319437 @default.
• W4206296392 hasAuthorship W4206296392A5058684604 @default.
• W4206296392 hasAuthorship W4206296392A5062737955 @default.
• W4206296392 hasAuthorship W4206296392A5068205782 @default.
• W4206296392 hasBestOaLocation W42062963921 @default.
• W4206296392 hasConcept C101544691 @default.
• W4206296392 hasConcept C121608353 @default.
• W4206296392 hasConcept C126322002 @default.
• W4206296392 hasConcept C146285616 @default.
• W4206296392 hasConcept C14858245 @default.
• W4206296392 hasConcept C167734588 @default.
• W4206296392 hasConcept C170493617 @default.
• W4206296392 hasConcept C180361614 @default.
• W4206296392 hasConcept C184235292 @default.
• W4206296392 hasConcept C185592680 @default.
• W4206296392 hasConcept C202751555 @default.
• W4206296392 hasConcept C2775960820 @default.
• W4206296392 hasConcept C2777025900 @default.
• W4206296392 hasConcept C2777411675 @default.
• W4206296392 hasConcept C2778820342 @default.
• W4206296392 hasConcept C2779490328 @default.
• W4206296392 hasConcept C2780124434 @default.
• W4206296392 hasConcept C2780394083 @default.
• W4206296392 hasConcept C42362537 @default.
• W4206296392 hasConcept C502942594 @default.
• W4206296392 hasConcept C55493867 @default.
• W4206296392 hasConcept C71924100 @default.
• W4206296392 hasConcept C86803240 @default.
• W4206296392 hasConcept C97029542 @default.
• W4206296392 hasConcept C98274493 @default.
• W4206296392 hasConceptScore W4206296392C101544691 @default.
• W4206296392 hasConceptScore W4206296392C121608353 @default.
• W4206296392 hasConceptScore W4206296392C126322002 @default.
• W4206296392 hasConceptScore W4206296392C146285616 @default.
• W4206296392 hasConceptScore W4206296392C14858245 @default.
• W4206296392 hasConceptScore W4206296392C167734588 @default.

• next